Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From MEDRx Co., Ltd.

Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress

Alongside a build-up in the US, Cipla is keeping a sharp eye on its “profitability profile” in this market and expects to rationalize products that don’t fit the bill. But it remains on track to establishing a respiratory franchise in key regulated markets, with generic Advair studies moving forward in the US.

Commercial Strategy

Cipla Revs Up In US, Newer Markets To Cushion Against Volatility

US scale-up plans, cost optimization and a deeper push in certain other markets to garner volumes and as a buffer against volatility were some of the key strategies discussed by Cipla’s CEO at the recent J.P. Morgan Healthcare Conference in San Francisco.

Commercial Strategy

Cipla Primes For US Momentum But Seretide Generic Is Slow In UK

Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.

Generic Drugs Strategy

Cipla Primes For US Momentum But Seretide Generic Is Slow In UK

Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.

Generic Drugs Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • IL Pharma, Inc. (US Subsidiary)
UsernamePublicRestriction

Register